Biochemical Markers and 2 and 3D Ultrasound to ID Maternal & Fetal Complications
Can a combination of prenatal screening blood tests, early ultrasound, and a 3D ultrasound of the fetal face at approximately 20 weeks gestation identify fetuses with congenital anomalies and predict maternal and fetal complications?
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||The Combination of Biochemical Markers and Two and Three Dimensional Ultrasound Using Geometric Morphometrics in the Identification of Congenital Anomalies and Maternal or Fetal Complications|
- Correlation of geometric morphometric analysis of fetal brow to 10 soft markers [ Time Frame: completion of pregnancy ] [ Designated as safety issue: No ]In patients who have undergone step-wise sequential screening, how often will the evaluation of 10 midtrimester sonographic soft markers of aneuploidy such that the recommendation regarding invasive diagnostic testing be changed?
|Study Start Date:||March 2009|
|Estimated Study Completion Date:||December 2014|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Pts will be consented upon presenting to the department for a comprehensive ultrasound.The 3D picture is the only part of the study that is not part of standard obstetrical care.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01404221
|United States, New York|
|Prenatal Testing department, North Shore University Hospital|
|Manhasset, New York, United States, 11030|
|Principal Investigator:||Burton Rochelson, MD||North Shore-LIJ Health System|